Rein Therapeutics Share Holder Equity 2017-2024 | RNTX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Rein Therapeutics share holder equity from 2017 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Rein Therapeutics share holder equity from 2017 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$147B
Gilead Sciences (GILD)	$116B
Bristol Myers Squibb (BMY)	$115.8B
Vertex Pharmaceuticals (VRTX)	$110.2B
CSL (CSLLY)	$81.9B
Regeneron Pharmaceuticals (REGN)	$74.7B
GSK (GSK)	$69.3B
Argenex SE (ARGX)	$38.6B
Alnylam Pharmaceuticals (ALNY)	$34.4B
BioNTech SE (BNTX)	$27.6B
Illumina (ILMN)	$22.3B
BeiGene (ONC)	$21.7B
Biogen (BIIB)	$20.8B
Moderna (MRNA)	$14.8B
Insmed (INSM)	$14B
Incyte (INCY)	$13.9B
Genmab (GMAB)	$13.9B
Genmab (GNMSF)	$13.9B
Intra-Cellular Therapies (ITCI)	$13.5B
Bio-Techne Corp (TECH)	$12.5B
BioMarin Pharmaceutical (BMRN)	$11.8B
Sarepta Therapeutics (SRPT)	$11.1B
Vaxcyte (PCVX)	$10.8B
QIAGEN (QGEN)	$10.8B
Exact Sciences (EXAS)	$10.1B
Swedish Orphan Biovitrum (BIOVF)	$10.1B
Bio-Rad Laboratories (BIO.B)	$9.8B
Exelixis (EXEL)	$9.4B
Repligen (RGEN)	$9.3B
Roivant Sciences (ROIV)	$8.1B